• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Donate Now
  • Sign Up

Center for Medicare Advocacy

Advancing Access to Medicare and Healthcare

  • Eligibility/Enrollment
  • Coverage/Appeals
    • Medicare Costs (2020 & 2021)
    • Self Help Materials – Toolkits & More
  • Topics
    • Basic Introduction to Medicare
    • COVID-19 and Medicare
    • Medicare Costs (2020 & 2021)
    • Home Health Care
    • Improvement Standard and Jimmo News
    • Nursing Home / Skilled Nursing Facility Care
    • Outpatient Observation Status
    • Part B
    • Part D / Prescription Drug Benefits
    • Medicare for People Under 65
    • Medicare “Reform”
    • All Other Topics
    • Resources
      • Infographics
  • Publications
    • CMA Alerts
    • Fact Sheets & Issue Briefs
    • Infographics
    • The Medicare Handbook
    • SNF Enforcement Newsletter
    • Elder Justice Newsletter
    • Medicare Facts & Fiction
    • Articles by Topic
  • Litigation
    • Litigation News
    • Cases
    • Litigation Archive
    • Amicus Curiae Activities
  • Newsroom
    • Press Releases
    • Editorials & Letters to the Editor
    • CMA Comments, Responses, and Letters
    • Medicare Facts & Fiction
    • CMA in the News
  • About Us
    • Mission Statement
    • CMA FAQs
    • Personnel & Boards
    • The Center for Medicare Advocacy Founder’s Circle
    • Connecticut Dually Eligible Appeals Project
    • Ossen Medicare Outreach, Education and Advocacy Project
    • National Medicare Advocates Alliance
    • National Voices of Medicare Summit
    • CMA Webinars
    • Products & Services
    • Testimonials
    • Career, Fellowship & Internship Opportunities
    • Contact Us
  • Support Our Work
    • Donate Now
    • Join the Center for Medicare Advocacy Founder’s Circle
    • Take Action
    • Share Your Health Care Story
    • Tell Congress to Protect Our Care
    • Listen to Medicare & Health Care Stories
    • Sign Up

MS Drug, Tysabri, Suspended

March 1, 2005

Print Friendly, PDF & Email

On February 28, 2005 the manufacturers of Tysabri, Biogen Idec and Elan Corporation, announced the voluntary suspension of the Multiple Sclerosis drug from the market and from all clinical trials.  According to the companies’ press release:

This decision is based on very recent reports of two serious adverse events that have occurred in patients treated with TYSABRI in combination with AVONEX (Interferon beta-la) in clinical trials.  These events involve one fatal, confirmed case and one suspected case of progressive multifocal leukoencephalopathy (PML), a rare and frequently fatal, demyelinating disease of the central nervous system.  Both patients received more than two years of TYSABRI therapy in combination with AVONEX.

According to the press release, concerned patients and physicians should call 1-888-489-7227.

The Center for Medicare Advocacy has an agreement with the National Multiple Sclerosis Society to help MS Society staff better understand Medicare and to help people with MS obtain the Medicare coverage to which they are entitled for necessary health care. The Center is providing in-house, audio, and web-based training, written and web-based information, and advocacy services for the National MS Society, its Information & Referral Center, and other staff members.  For more information about this collaboration, please contact attorney Terry Berthelot at (860) 456-7790 or tberthel@medicareadvoacy.org(remove spaces). 

For direct assistance with Medicare issues for people with MS, contact the MS Information and Referral Center.  Call 1 (800) FIGHT MS, or visit "Information and Referral" in the "Client Services" section of your local chapter's website.  Click HERE to find your local chapter.

Filed Under: archived Tagged With: Chronic Conditions, Medicare Part D / Prescription Drugs, Multiple Sclerosis

Primary Sidebar

Easy Access to Understanding Medicare

The Center for Medicare Advocacy produces a range of informative materials on Medicare-related topics. Check them out:

  • Medicare Basics
  • CMA Alerts
  • CMA Webinars
  • Connecticut Info & Projects
  • Health Care Stories
  • Se habla Español

Sign Up for CMA Alerts

Jimmo v. Sebelius

Medicare covers skilled care to maintain or slow decline as well as to improve.

Improvement Isn’t Required. It’s the law!

Read more.

Latest Tweets

  • Our statement with @CANHR_CA and the Michigan Elder Justice Initiative recommends key issues of the Nursing Home Re… https://t.co/9nSwt3tAwT, Jan 15
@CMAorg

Footer

Stay Connected:

  • Contact Us
  • Sitemap
  • Products & Services
  • Copyright/Privacy

© 2021 · Center for Medicare Advocacy